Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MMV390048 · 2 trials · 1 indication
Number of observed and self-reported Adverse Events (AE) (unexpected toxicities, adverse events encountered during or after investigational drug administration)
The effect of a single oral dose of MMV390048 on P. falciparum blood stage parasites in healthy volunteers with induced blood stage malaria as observed over a period of 28 days post dosing, through: * qPCR analysis of parasite clearance, and * calculation of the parasite reduction ratio (PRR)
| Arm | Type | Description |
|---|---|---|
| MMV390048 40 mg | EXPERIMENTAL | MMV390048 40 mg, tablets, single dose |
| Placebo to match MMV390048 40 mg | PLACEBO_COMPARATOR | Placebo to match MMV390048 40 mg, tablets, single dose |
| MMV390048 80 mg | EXPERIMENTAL | MMV390048 80 mg, tablets, single dose |
| Placebo to match MMV390048 80 mg | PLACEBO_COMPARATOR | Placebo to match MMV390048 80 mg, tablets, single dose |
| MMV390048 120 mg | EXPERIMENTAL | MMV390048 120 mg, tablets, single dose |
| Placebo to match MMV390048 120 mg | PLACEBO_COMPARATOR | Placebo to match MMV390048 120 mg, tablets, single dose |
| MMV390048 dose to be determined mg | EXPERIMENTAL | MMV390048 dose to be determined mg, tablets, single dose |
| Name | Type | Description |
|---|---|---|
| MMV390048 40 mg | DRUG | - |
| Placebo to match MMV390048 40 mg | DRUG | - |
| MMV390048 80 mg | DRUG | - |
| Placebo to match MMV390048 80 mg | DRUG | - |
| MMV390048 120 mg | DRUG | - |
| Placebo to match MMV390048 120 mg | DRUG | - |
| MMV390048 40mg | DRUG | - |
| MMV390048 dose to be determined mg | DRUG | Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined. |
Inclusion Criteria: 1. Completion of the written informed consent process. 2. Men or WNCBP age 18 to 55 years, in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. 3. Male subjects agree to use acceptable meth...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | Tafenoquine, Primaquine, Chloroquine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
MMV390048 is an investigational small molecule being developed for the treatment of malaria. It is currently in Phase 1 clinical development and has been studied in healthy adult volunteers to evaluate its safety, tolerability, and antimalarial activity against Plasmodium falciparum.
MMV390048 is being developed by CNS Pharmaceuticals, Inc., a company traded on the NASDAQ under the ticker symbol CNSP. The drug is in Phase 1 clinical development for malaria.
MMV390048 is a small molecule antimalarial agent. It has demonstrated antimalarial activity against Plasmodium falciparum in clinical studies. The specific molecular target of the drug has not been disclosed in the available clinical trial information.
MMV390048 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy adult volunteers. The drug is investigational and has not been approved by regulatory authorities.
MMV390048 has been studied in two completed Phase 1 clinical trials. The first trial, NCT02783820, assessed safety, tolerability, and pharmacokinetics of ascending oral doses. The second trial, NCT02783833, evaluated its antimalarial activity against Plasmodium falciparum. Both trials were conducted in Australia.
MMV390048 is a distinct investigational small molecule developed for malaria. It has been studied as a single agent in Phase 1 trials. No alternative names for this drug have been reported in the clinical trial records.